PCN101 Real-World Economic Outcomes of First-Line (1L) Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.193
https://www.valueinhealthjournal.com/article/S1098-3015(21)00410-1/fulltext
Title : PCN101 Real-World Economic Outcomes of First-Line (1L) Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00410-1&doi=10.1016/j.jval.2021.04.193
First page :
Section Title :
Open access? : No
Section Order : 10769
Categories :
Tags :
Regions :
ViH Article Tags :